When a GLP-1 receptor agonist goes on top of basal insulin, the instinct is to treat it as an addition. It is at least as much a de-escalation opportunity.
Two mechanisms push the same direction. Glycaemia improves, so the existing basal dose becomes relatively larger. And the gastrointestinal effects during titration reduce oral intake for some patients, sometimes markedly, in the same weeks. A basal dose that was correct last month can become a hypoglycaemia risk without anything else changing.
Practical handling: review the basal dose at initiation rather than at the next routine visit, warn patients that reduced appetite is expected rather than alarming, and make sure they know the threshold at which to contact you instead of simply skipping doses. Patients on a fixed dose with no review scheduled are the ones who get into trouble.
Note that in ACHIEVE-5 insulin glargine was actively titrated in every arm, including placebo. Trial protocols do that systematically. Clinics often do not.
- Review basal insulin at GLP-1 initiation, not at the next routine review
- Falling appetite during titration compounds the glycaemic effect
- Tell patients reduced intake is expected, and when to call rather than skip
- Trial protocols titrate insulin systematically; real-world follow-up often lags
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free